Skip to main content
Premium Trial:

Request an Annual Quote

Seegene Signs Japan Marketing Deal with Eidia

NEW YORK (GenomeWeb News) – Seegene announced today that it has signed an agreement with Eidia to market the firm's molecular diagnostic products in Japan.

Under the deal, Eidia, which is the diagnostics subsidiary of Eisai, will have access to Seegene's TOCE (tagging oligonucleotide capture and extension) multiplex molecular diagnostic tests. The Japanese firm will exclusively market and distribute the tests in Japan, and it will seek regulatory clearance from the Japanese Pharmaceutical and Medical Device Agency.

"Our partnership with Eidia opens a significant sales channel for our novel diagnostic tests in Japan," Jong-Yoon Chun, founder, CTO, and CEO of Seegene, said in a statement. "We look forward to working with Eidia to improve patient healthcare with highly sensitive and specific multiplexed MoDx tests."

Further terms of the agreement were not disclosed.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.